Overexpression of nicotinamide phosphoribosyltransferase (NAMPT) has been described across a broad range of solid tumors including ovarian, colorectal, breast, gastric, prostate, and endometrial carcinomas in addition with melanoma, gliomas, and astrocytomas indicating that inhibition of NAMPT may be used as a cancer treatment strategy [70]. The gene discussed is NAMPT; the disease is glioma.